ArticleScientific reports2020
Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Biological variation and reference change value of the estimated glomerular filtration rate in humans: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Article
- Ethics of Personalised Medicine: Importance of the Multidisciplinary Approach in KidneySign Project.Proteomics · 2025Article
- Distinct Urinary Proteome Changes Across Estimated Glomerular Filtration Rate Stages in a Cohort of Black South Africans.International journal of molecular sciences · 2025Article
- Article
- Higher circulating levels of non-esterified fatty acids are associated with faster kidney function decline in post-menopausal women with type 2 diabetes: a pilot prospective study.Acta diabetologica · 2024Article
- Use of novel structural features to identify urinary biomarkers during acute kidney injury that predict progression to chronic kidney disease.BMC nephrology · 2023Article
- Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores.Journal of clinical medicine · 2023Article
- Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study.Cardiovascular diabetology · 2023Article
- Candidate composite biomarker to inform drug treatments for diabetic kidney disease.Frontiers in medicine · 2023Article
- Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease.Theranostics · 2023Article
- Article
- GWAS of longitudinal trajectories at biobank scale.American journal of human genetics · 2022Article
- Article
- A prediction model for the decline in renal function in people with type 2 diabetes mellitus: study protocol.Diagnostic and prognostic research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies reporting on biomarkers aiming to predict adverse renal outcomes in patients with type 2 diabetes and kidney disease (DKD) conventionally define a surrogate endpoint either as a percentage of decrease of eGFR (e.g. ≥ 30%) or an absolute decline (e.g. ≥ 5 ml/min/year). The application of those study results in clinical practise however relies on the assumption of a linear and intra-individually stable progression of DKD. We studied 860 patients of the PROVALID study and 178 of an independent population with a relatively preserved eGFR at baseline and at least 5 years of follow up. Individuals with a detrimental prognosis were identified using various thresholds of a percentage or absolute decline of eGFR after each year of follow up. Next, we determined how many of the patients met the same criteria at other points in time. Interindividual eGFR decline was highly variable but in addition intra-individual eGFR trajectories also were frequently non-linear. For example, of all subjects reaching an endpoint defined as a decrease of eGFR by ≥ 30% between baseline and 3 years of follow up, only 60.3 and 45.2% lost at least the same amount between baseline and year 4 or 5. The results were similar when only patients on stable medication or subpopulations based on baseline eGFR or albuminuria status were analyzed or an eGFR decline of ≥ 5 ml/min/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.